BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $89 | -10.1% | 1,200 | 0.0% | 0.03% | -13.3% |
| Q4 2022 | $99 | -99.9% | 1,200 | +300.0% | 0.03% | +7.1% |
| Q3 2022 | $85,000 | -18.3% | 300 | 0.0% | 0.03% | -9.7% |
| Q2 2022 | $104,000 | -20.0% | 300 | 0.0% | 0.03% | -8.8% |
| Q1 2022 | $130,000 | -16.1% | 300 | 0.0% | 0.03% | -15.0% |
| Q4 2021 | $155,000 | +6.9% | 300 | 0.0% | 0.04% | -2.4% |
| Q3 2021 | $145,000 | +7.4% | 300 | 0.0% | 0.04% | +5.1% |
| Q2 2021 | $135,000 | +17.4% | 300 | 0.0% | 0.04% | -4.9% |
| Q1 2021 | $115,000 | +21.1% | 300 | 0.0% | 0.04% | +7.9% |
| Q4 2020 | $95,000 | +28.4% | 300 | 0.0% | 0.04% | +15.2% |
| Q3 2020 | $74,000 | -6.3% | 300 | 0.0% | 0.03% | -13.2% |
| Q2 2020 | $79,000 | +38.6% | 300 | 0.0% | 0.04% | +18.8% |
| Q1 2020 | $57,000 | -13.6% | 300 | 0.0% | 0.03% | +3.2% |
| Q4 2019 | $66,000 | +11.9% | 300 | 0.0% | 0.03% | 0.0% |
| Q3 2019 | $59,000 | -6.3% | 300 | 0.0% | 0.03% | -8.8% |
| Q2 2019 | $63,000 | +5.0% | 300 | 0.0% | 0.03% | -2.9% |
| Q1 2019 | $60,000 | +39.5% | 300 | 0.0% | 0.04% | +25.0% |
| Q4 2018 | $43,000 | -29.5% | 300 | 0.0% | 0.03% | -26.3% |
| Q3 2018 | $61,000 | +38.6% | 300 | 0.0% | 0.04% | +26.7% |
| Q2 2018 | $44,000 | -2.2% | 300 | 0.0% | 0.03% | -9.1% |
| Q1 2018 | $45,000 | +15.4% | 300 | 0.0% | 0.03% | +22.2% |
| Q4 2017 | $39,000 | +8.3% | 300 | 0.0% | 0.03% | +8.0% |
| Q3 2017 | $36,000 | +2.9% | 300 | 0.0% | 0.02% | -3.8% |
| Q2 2017 | $35,000 | +16.7% | 300 | 0.0% | 0.03% | +13.0% |
| Q1 2017 | $30,000 | -3.2% | 300 | 0.0% | 0.02% | -4.2% |
| Q4 2016 | $31,000 | -6.1% | 300 | 0.0% | 0.02% | -4.0% |
| Q3 2016 | $33,000 | – | 300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |